Highlights
So for schizophrenia, other than a real cure for schizophrenia, it would probably be the cognitive deficit if I had to pick one thing. There’s lots and lots of pressing needs. We’re not really treating anything in schizophrenia particularly well. Even the patients who do great on the best medications out there in schizophrenia are most often permanently disabled. But, if I had to pick one thing in schizophrenia it would probably be treating cognitive deficits.
I think we need better antidepressants for bipolar, for bipolar depression rather. Lurasidone and the antipsychotics are OK for a lot of people. We’re definitely in better shape than we were about 10 years ago before these medications were developed. However, we’re still giving, for the most part, people that are not psychotic these antipsychotics which have really serious long-term side effects. I would like to avoid that and find a more specific treatment for bipolar depression without giving them an antipsychotic, plus something that would work better for more people.
Overview
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.